BEZ235 Trial in Patients With Advanced Endometrial Carcinoma

Exclusion Criteria

• •Previous treatment with PI3K and/or mammalian Target Of Rapamycin (mTOR) inhibitors
• •More than one line of prior treatment for advanced or metastatic disease
• •Active uncontrolled or symptomatic Central Nervous System (CNS) metastases
• •Concurrent malignancy or malignancy in the last 3 years prior to start of study treatment
• •Wide field radiotherapy ≤ 28 days or limited field radiation for palliation ≤ 14 days prior to enrollment in this study
• •Active cardiac disease (e.g. Left Ventricular Ejection Fraction (LVEF) \< 50%, Q-T interval corrected for heart rate (QTcF) \> 480 msec on screening Electrocardiogram (ECG), unstable angina pectoris, ventricular, supraventricular or nodal arrhythmias)
• •Inadequately controlled hypertension
• •Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BEZ235
• •Drugs with a known risk to induce Torsades de Pointes, moderate and strong inhibitors or inducers of CYP3A4, warfarin and coumadin analogues, Luteinizing Hormone-Releasing Hormone (LHRH) agonists
• •Pregnant or nursing (lactating) woman